Definium tees up regulatory submission for psychedelic on Phase III hat trick

Definium Therapeutics plans to submit an NDA for LSD-based psychedelic ... Staunch biotech competition spurs new secretive tactics, shifts investor.

Share this story

Surfaced by this Google Alert